Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As Amgen's Prolia Goes, So Goes The Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Wall Street analysts' reactions are mixed as to the meaning of an FDA advisory committee's mixed votes on Amgen's denosumab.
Advertisement

Related Content

Amgen's Mixed Advisory Committee Votes On Prolia Still Offer A Good Start
Amgen's Mixed Advisory Committee Votes On Prolia Still Offer A Good Start
GSK Denosumab Deal Gives Amgen A Leg Up In Primary Care
Amgen, GSK To Team Up On Denosumab Commercialization in Europe
Why Doesn't Pharma Get Smaller?

Topics

Advertisement
UsernamePublicRestriction

Register

PS069840

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel